The mechanism by which agonist binding to an ionotropic glutamate receptor leads to channel opening is a central issue in molecular neurobiology. Partial agonists are useful tools for studying the activation mechanism because they produce full channel activation with lower probability than full agonists. Structural transitions that determine the efficacy of partial agonists can provide information on the trigger that begins the channel opening process. The ligand-binding domain of AMPA receptors is a bilobed structure, and the closure of the lobes is associated with channel activation. One possibility is that partial agonists sterically block full lobe closure but that partial degrees of closure trigger the channel with a lower probability. Alternatively, full lobe closure may be required for activation, and the stability of the fully closed state could determine efficacy, with the fully closed state having a lower stability when bound to partial relative to full agonists. Disulfide trapping experiments demonstrated that even extremely low efficacy ligands, such as CNQX, can produce a full lobe closure, presumably with low probability. The results are consistent the hypothesis that the efficacy is determined at least in part by the stability of the state in which the lobes are fully closed.
propionic acid (AMPA; GluA1-4); (2) the neurotoxin kainate (GluK1-5); and (3) N-methyl-D-aspartic acid (NMDA; GluN1, GluN2A-D, GluN3A-B). The important structural details of glutamate receptors were determined first by the solution of the structures of the ligand binding domain (3) (4) (5) (6) (7) and the N-terminal domain (8, 9) followed by the structure of the full-length tetrameric GluA2 subtype of AMPA receptor (10) . The structures in the presence of various agonists, partial agonists, and antagonists in combination with spectroscopic measurements, electrophysiological measurements, and sitedirected mutagenesis have provided a wealth of information on the link between structure and function (11) (12) (13) . The binding domain is a bilobed structure to which agonist binds in the cleft between the two lobes. Two linker peptide strands connect the lobes, and the lobes can close to envelope the agonist. One lobe (Lobe 1) forms a dimer interface with a second copy of the ligandbinding domain within the tetrameric structure, and the second lobe (Lobe 2) is linked to the ion channel domain. When the dimer interface is intact, the force generated by the closing of the lobes can affect the ion channel and presumably open a gate allowing ions to traverse the channel. Complexities arise due to the tetrameric structure and subtle differences between glutamate receptor subtypes, but the general outline of channel activation is likely to be similar across this class of receptor.
The mechanism of channel activation by partial agonists remains unclear. Single channel recording measurements of AMPA receptors have demonstrated that three or four conductance levels can be observed from a single channel and these conductance levels are the same for both full and partial agonists (12, 14) . Population of the higher conductance levels is favored at higher agonist concentrations, but at any given concentration, higher conductance levels are more prevalent for full than partial agonists. The concentration dependence is consistent with a model in which each subunit has a "gate" that contributes to ion conductance, and the more gates that are open, the higher the conductance. However, given the fact that the conductance levels are the same for all agonists, this would suggest that opening of a gate is an all-or-nothing process. That is, the signal from the ligand-binding domain results in a concerted change in the structure of the channel region. The question then is whether that change is produced by a specific conformation of the ligandbinding domain (such as a full lobe closure) or whether multiple conformations can produce the same change, perhaps with different probabilities, or possibly some combination of the two models can explain channel activation.
The initial crystal structures of the GluA2 ligand-binding domain in the presence of partial agonists suggested a correlation between the degree of lobe closure and the efficacy of the ligand, suggesting that multiple conformations can trigger channel gating. A full closure would result in a high probability of gating, and with a partial closure, the probability of gating would be much lower. However, subsequent studies indicated that at least some partial agonists could assume a range of lobe closures (15) and even the correlation in crystal structures between lobe opening and efficacy does not always hold (16) (17) (18) . Most strikingly, crystal structures of partial agonists of the NMDA receptor show a fully closed lobe (19) , leading to the suggestion that partial agonism is fundamentally different for NMDA vs. AMPA receptors. An alternative view of partial agonism is that the stability of full lobe closure dictates efficacy (13, 15) . That is, partial agonists could potentially exist in a dynamic equilibrium among two or more conformations. Some of the conformations may have relative lobe orientations that are open (similar to that seen in some crystal structures, 3, 12) and other conformations that may be closed to the same extent as that seen for full agonists (3). According to this hypothesis, channel activation would require the fully closed form, and the stability of that form would dictate efficacy. The binding of some weak partial agonists, such as iodowillardiine (IW), are consistent with this idea in that a wide range of lobe closures have been observed in crystal (12, 20) and NMR structures (15) and evidence for large scale dynamics is present in the NMR spectra (15, 21) . Also, mutations that decrease the efficacy of AMPA show a range of lobe orientations as measured using single molecule FRET (22) . In contrast, the weak partial agonist, kainate, presents a structural impediment to lobe closure. The isoprenyl group of kainate seems to block the closure of the lobe because of an apparent steric clash with the sidechain of L650 in GluA2 (3). Mutation of L650 to threonine increases kainate efficacy presumably by reducing the steric interaction between this position and the isoprenyl of kainate (16, 18) . Furthermore, little evidence for µs-ms timescale dynamics in the presence of kainate have been observed in NMR studies (23) . However, structures of GluA3 (24) and GluA4 (25) in the presence of kainate are more closed than GluA2 and the D651A mutation of GluA3 results in even further closure of the lobes due to a rotation of the sidechain of L650 (GluA2 numbering; Holley et al., submitted).
Cysteine trapping studies (i.e., the introduction of two cysteines to determine if a disulfide can form) have been used to determine proximity of different portions of one protein or the proximity of two proteins or subunits. One criticism of this method is that proteins are dynamic structures and very rare conformations can potentially be trapped. In this case, the shortcoming of the method can be an advantage. If, in fact, partial agonists can activate the channel by a relatively rare transition to a conformation with fully closed lobes, then cysteine trapping should be capable of stabilizing this form for further analysis by X-ray crystallography, NMR spectroscopy and radioligand binding. We show here that with glutamate, iodowillardiine, kainate, and CNQX bound, the A452C/S652C GluA2 ligand-binding domain can be trapped in the closed form.
Experimental Procedures:
Materials. UBP282 and IW were purchased from Tocris (Ellisville, MO), and kainate, CNQX, and DNQX were purchased from Ascent Scientific (Princeton, NJ). Glutamate was purchased from Sigma-Aldrich (St. Louis, MO). The GluA2 S1S2J construct was obtained from Eric Gouaux (Vollum Institute; 3 Mutagenesis. Mutant receptors for both full length GluA2 and the LBD of GluA2 were generated by QuikChange site-directed mutagenesis using Phusion or Pfu polymerase. The mRNAs for oocyte injection experiment were synthesized using a T7 high yield transcription kit following the instructions of the manufacturer (Aligent Technologies, Santa Clara, CA).
Cell culture and heterologous expression. HEK293 cells were cultured with DMEM/F12 supplemented with 10% newborn calf serum and antibiotics. Cells were transfected with 500 ng wild type or mutant receptors using Turbofect reagents (Fermentas Inc.). Cells were plated on poly-D-lysine (0.1 mg/ml) and collagen (1:100 dilution of 10 mg/ml solution) double-coated chambered coverslides or 96-well plates for immunofluorescence or ratiometric fura-2 imaging experiments respectively. Stage VI oocytes were prepared from isolated ovaries of Xenopus tropicalis (26) , and injected with 7 ng of cRNA for each receptor (both wildtype and mutants). Oocytes were kept in physiological OR-2 solution with antibiotics for 3-7 days before recording.
Electrophysiology. All electrophysiology experiments were conducted at room temperature (21°C) using the two-electrode voltage clamp method. The standard extracellular solution was composed of (in mM) 5 HEPES, 96 NaCl, 1 MgCl 2 , 1 CaCl 2 , pH 7.4. 10 mM sodium glutamate was added for agonist-dependent activation. The membrane holding potential was -60 mV. A voltage ramp from -100 to +80 mV of 250 ms duration given at 1 Hz was used to continuously monitor the currents.
Ratiometric Ca 2+ imaging. Cells expressing wildtype or mutant GluA2 were loaded with fura-2 AM (5 µM) for 2 h. Imaging experiments were carried out at room temperature (22ºC), with a sampling rate of one frame every 2 seconds with 100 ms exposure time to either wavelength (340 and 380 nm). Images were acquired using a CCD camera driven by the Slidebook 4.2 software.
Immunofluorescence imaging. HEK293 cells were transiently transfected with 500 ng of cDNA (WT, double mutant) using TurboFect (Fermentas) Protein Preparation and Purification of LBD. The GluA2 LBD consists of residues N392 -K506 and P632 -S775 of the full rat GluA2-flop subunit (27) with and without the A452C/S652C mutations, a 'GA' segment at the N-terminus, and a 'GT' linker connecting K506 and P632 (3). pET22b(+) plasmids were transformed in E. coli strain Origami B (DE3) cells and were grown at 37˚C to OD600 of 0.9 to 1.0 in LB medium supplemented with antibiotics (ampicillin and kanamycin). The cultures were cooled to 20˚C for 20 min and isopropyl-β-D-thiogalactoside (IPTG) was added to a final concentration of 0.5 mM. Cultures were allowed to grow at 20˚C for 20 h. The cells were then pelleted and the LBD purified using a Ni-NTA column, followed by thrombin cleavage of the 6HIS-tag, a sizing column (Superose 12, XK 26/100), and finally an HT-SP-ion exchangeSepharose column (Amersham Pharmacia). Glutamate (1 mM) was maintained in all buffers throughout purification. After the last column, the protein was concentrated and stored in 20 mM sodium acetate, 1 mM sodium azide, and 10 mM glutamate at pH 5.5. Final concentrations of CNQX, DNQX, kainate, IW, and UBP282 were 3 mM. Ligands were exchanged using successive dilution and concentration using an Amicon Ultra-4 (10K) filter. For NMR spectroscopy, the bacteria were grown in M9 media with 15 N-ammonium chloride as the sole nitrogen source and 13 Cglucose as the sole carbon source. The NMR buffer was an aqueous solution of 25 mM sodium acetate, 25 mM sodium chloride, 1 mM sodium azide, 12% D 2 O, pH 5.0.
NMR Spectroscopy. All measurements were made on a Varian Inova 500 spectrometer equipped with a triple resonance, z-gradient cryogenic probe. The standard double and triple resonance experiments in the BioPack software suite (Varian, Palo Alto) were used. Spectra were collected at 25˚C for glutamate, kainate and IW, and at 13˚C for CNQX, DNQX, and UBP282. The data were apodized with a mixed exponentialGauss window function and zero-filled to double the original number of data points before Fourier transform (NMRPipe v. 1.6 (28)). Spectra were displayed and the peaks chosen and measured using Sparky (29) .
Crystallography. For crystallization trials, the protein was concentrated to 0.3 to 0.4 mM using a Centricon 10 centrifugal filter (Millipore, Bedford, MA). The final protein concentration was approximately 0.3 mM. Crystals were grown at 4˚C using the hanging drop technique, and the drops contained a 1:1 (v/v) ratio of protein solution to reservoir solution. The reservoir solution contained 16-18% PEG 8K, 0.1 M sodium cacodylate, 0.1-0.15 M zinc acetate, pH 6.5.
Data were collected at the Cornell High Energy Synchrotron Source beam line A1 using a Quantum-210 Area Detector Systems chargecoupled device detector. Data sets were indexed and scaled with HKL-2000 (30) . Structures were solved with molecular replacement using Phenix (31) . Refinement was performed with Phenix (31) and the CCP4 Program Suite 6.1.13 (32) , and Coot 0.6.1 (33) was used for model building.
Radioligand binding. 
]AMPA (10 nM) was added, the reaction (200 µl) proceeded for 1 hour followed by filtration through Millipore GSWP filters and two 2 ml washes with binding buffer. All analysis was done using Kaleidagraph (Synergy Software).
RESULTS

Lobe locking mutations.
The ligand-binding domain of GluA2 contains four cysteines. Two (C722 and C773) are involved in a disulfide bond that ties Lobe 2 to the C-terminal region of the domain in Lobe 1 ( Figure 1A) . The other two (C425 and C435) are not near the lobe interface and were predicted not to interfere with introduction of cysteines designed to maintain lobe closure. Two sets of double cysteine mutations were made on a wildtype background of the GluA2 LBD: A452C/S652C and V484C/E657C. Both expressed well in E. coli, and produced high quality NMR spectra when uniformly labeled with 15 N.
The 1 H, 15 N-HSQC spectrum of V484C/E657C bound to glutamate was unchanged when exposed to either Cu-phenanthroline or DTT ( Figure S1A ). On the other hand, A452C/S652C bound to glutamate was unchanged relative to untreated protein when exposed to Cuphenanthroline, but the spectrum was markedly changed in the presence of DTT ( Figure 1A ). The spectrum reverted to that seen in the presence of Cu-phenathroline when DTT was removed. The chemical shift changes were largely restricted to the lobe interface, suggesting that the disulfide bond was formed and broken by the reducing agent. This suggests that the disulfide bond is easily formed even in the absence of oxidizing agents when the protein is bound to glutamate, but can be reduced. This was confirmed in the crystal structures of A452C/S652C, which showed a clear disulfide bond (Figure 2A ). In the case of V484C/E657C, the sulfur atoms of the two cysteines were separated by 5.41 ± 0.16 Å even after exposure to Cu-phenanthroline ( Figure S1B ). All subsequent experiments employed the A452C/S652C mutation.
Reduction of disulfide bond revealed by radioligand binding. Radioligand binding was used to demonstrate that the lobes could be locked in a conformation that prevents further binding. Both wildtype and A452C/S652C GluA2 LBD were diluted to 40 nM, reduced with either DTT or β-ME and washed by successive dilution and concentration to remove residual glutamate. The sample was divided in two. One half was washed further with DTT or β-ME and the other was washed simply with buffer. Binding of [ 3 H]AMPA was then measured as a function of AMPA concentration. In the case of wildtype LBD, the binding was decreased somewhat by the reducing agent ( Figure 3A) , possibly due to a partial reduction of the native C718/C773 disulfide bond in the apo state. For the A452C/S652C mutation, binding was only observed in the reduced state, with no binding detected in the absence of reducing agent. Reduction of the disulfide bond by β-ME peaked at 5 mM, with a decrease in binding at higher concentrations of the reducing agent ( Figure 3B) . Also, the reduction of the disulfide bond was relatively slow, with a maximum reduction occurring after about 1 hour, as judged by the increase in binding sites for [ 3 H]AMPA ( Figure 3C ).
Lobe locking with partial agonists. While full agonists seem to act by binding and closing the lobes of the LBD fully, the action of partial agonists is less well understood. One possibility is that the bulkier partial agonists induce a stable partial lobe closing that, by some unknown mechanism, results in a lower probability of channel gating. Another alternative is that despite the apparent steric conflict implied by crystal structures, lobes can close fully (or almost fully) around a partial agonist, although less often than seen with full agonists. Nevertheless, a full closure may be required to activate the channel gate. Since the gate would be less likely to be activated, the efficacy of the agonist would be decreased relative to full agonists. The question asked here is whether partial agonists can close the channel fully, even if rarely.
Iodowillardiine and kainate: NMR spectroscopy. Two weak partial agonists were tested: IW and kainate. In both cases, NMR spectroscopy was used to determine if effects were uniform or whether both oxidized and reduced protein could be detected. Exchange of ligand was done in the presence of 50 mM DTT to remove glutamate and allow binding of the partial agonist. The 1 H, 15 N-HSQC (TROSY) NMR spectra (after the removal of DTT) are shown in Figures 1B (IW) and 1C (kainate). Addition of CuPhenanthroline had no effect on the spectra, suggesting that either the disulfide bond formed spontaneously or not at all. However, addition of DTT, resulted in a clear change in the spectrum. Because of the mutations, the chemical shifts of the mutant were changed sufficiently relative to the wildtype (35) to make assignment by proximity problematic in some regions of the spectrum. For this reason, assignments were verified with a combination of triple resonance experiments (HNCO, HN(CO)CA, and HNCA). Mapping of the chemical shift changes to the structure of the protein suggests that most changes occur near the introduced disulfide and much less so at the native disulfide, suggesting that the interlobe disulfide is formed spontaneously but can be reduced. Furthermore, the spectra do not show multiple peaks for a given correlation, suggesting that the disulfide was largely formed. Given the sensitivity of the measurements, less than ~15% was in the reduced form in the absence of reducing agent or in the oxidized form in the presence of reducing agent.
Iodowillardiine and kainate: X-ray crystallography. The crystal structures of the IWand kainate-bound proteins were then determined. In both cases, the disulfide bond between A452C and S652C was clearly formed in all three copies in the asymmetric unit ( Figure 2B (IW) and 2C (kainate)). Interestingly, even in the presence of reducing agents, the disulfide bond was formed, suggesting that this form of the protein, while not the predominant form in solution, was preferentially crystallized.
In the case of kainate, the A452C/S652C protein crystallizes in the P22 1 2 1 space group with three copies in the asymmetric unit (similar to the wildtype bound to glutamate) in contrast to the wildtype kainate-bound protein, which crystallizes as P2, with one or two copies in the asymmetric unit (Table S1) (3, 18, 24, 25) . Previous crystal structures have suggested that kainate prevents further lobe closure due to the steric clash between the sidechain of L650 with the isoprenyl group of kainate (foot-in-the-door mechanism; 18). The more fully closed structure is produced largely by the rotation of the sidechain of L650 and a small movement of kainate toward Lobe 1. With these rather subtle movements, the distribution of structures of the kainate-bound protein approaches the degree of closure of the glutamate-bound protein, although the average structure is still slightly more open in the presence of kainate. Although the crystal packing differs in the wildtype vs. the double cysteine mutant, the lattice packing does not seem to be the distorting the structure, resulting in the differences seen here. Average lobe orientation of the wildtype protein bound to both kainate (P2 symmetry) and glutamate (P222 symmetry) in solution is similar to that seen in the crystals (15) .
In the case of iodowillardiine bound to wildtype GluA2 LBD, the distribution of lobe orientations is greater, with the zinc-free structure having a lobe opening of 6.9˚ ± 1.8˚ (12) and a zinc-containing structure having a lobe opening of 2.2˚ ± 0.5˚ (20) , with the NMR structure falling between these two values (5.3˚ ± 1.5˚; 15). In the mutant structure bound to IW, the lobes are open by 0.8˚ ± 0.9˚, essentially identical to the glutamate-bound structure ( Figure 2B) . Likewise, the H-bonds described above for the kainatebound structure have not been observed in IWbound wildtype structures, but are present in all three structures in the mutant. The willardiine ring and the iodo group are accommodated in the binding site by a rotation of the sidechain of M708.
CNQX and DNQX. CNQX and DNQX have classically been considered antagonists of AMPA and kainate receptors, but both compounds can activate AMPA receptors under some circumstances (36) (37) (38) . In this regard, they might be considered very weak partial agonists. Thus, one might expect that if a full lobe closure is required for activation, the lobes might close, albeit rarely, with CNQX or DNQX bound. The introduced cysteines may then trap the protein in the closed conformation. Indeed, the oxidized, CNQX-bound structure was crystallized with P2 1 2 1 2 symmetry, and the lobes were open only by 1.27˚ ± 1.36˚ relative to glutamate, with two of the three structures in the asymmetric unit having the a lobe orientation within the range observed for the wildtype LBD bound to glutamate ( Figure 4A ). The A452C/S652C disulfide was formed in all three copies in the asymmetric unit. Unlike the IW and kainate-bound oxidized structures, the D651/S652 peptide bond was not flipped, and the interlobe H-bonds were not formed. In the presence of reducing agent (4 mM β- 15 N-HSQC spectra were collected in the presence and absence of DTT ( Figure 4B ). Because of stability issues of the protein bound to DNQX, a full assignment with triple resonance experiments was problematic, but the spectrum clearly changed in the presence of DTT, suggesting that the disulfide can be formed. Tentative assignments based on the glutamatebound spectra, would place most of the changed resonances near the presumed disulfide bond. These results suggest that, for both DNQX and CNQX, the lobes can transiently assume a fully closed structure, consistent with their very weak agonist activity.
No lobe locking with an antagonist: If activation of the channel requires full lobe closure, then antagonists should prevent the formation of the interlobe disulfide. This was tested by reducing and exchanging the ligand for UBP282. UBP282 is a bulky willardiine derivative that produces lobe extension (i.e., lobe opening greater than the apo form; 39) and functions as a relatively low affinity antagonist of GluA2 (40) . The 1 H-15 N HSQC NMR spectra of Cu-Phenantroline-oxidized and DTT-reduced GluA2 LBD in the presence of UBP282 are shown in Figure 5 . Unlike a full agonist (glutamate), partial agonists (iodowillardiine and kainate) and very weak partial agonists (CNQX and DNQX), no difference was observed between the oxidized and reduced spectra, suggesting that the disulfide bond was not formed.
Effect of A452C/S652C mutation on cell surface expression: Individual mutations (A452C and S652C) were made in full length GluA2 i , and the proteins were expressed in Xenopus oocytes. We recorded glutamate-induced cationic currents in ooctyes expressing A452C mutant channels, which were of smaller amplitude than wildtype GluA2. In contrast, oocytes injected with S652C RNA had no recordable currents. We, therefore, tested whether the lack of functional current of S652C is dependent on the expression system and discovered that S652C did express in HEK293 cells as a functional channel, shown using glutamate-evoked Ca 2+ entry in ratiometric fura-2 imaging experiments ( Figure 6A ). In the case of the double mutation (A452C/S652C) expressed in either expression system, no currents or Ca 2+ transients were observed in response to glutamate even when cyclothiazide (an inhibitor of desensitization) and DTT or βME were included in the solution. This could be due to either a lack of expression, a dysfunctional receptor at the cell surface, or the failure of the protein to reach the cell surface. Using an antibody that recognizes an extracellular determinant, we compared the cell surface and total expression of A452C/S652C, S652C, and wildtype GluA2i, which are shown in Figure 6B . Clearly, the wildtype and single mutation traffic to the cell surface, but the double mutation (A452C/S652C), while being robustly expressed, is not found at the cell surface. Similar results were observed when the A452C/S652C mutation was expressed with stargazin, a TARP family protein that can increase the surface expression of AMPA receptors (41) .
DISCUSSION
The activation of AMPA receptors begins with binding of agonist and a global motion of the LBD, which in turn produces a change in the ion channel gate allowing cations to flow through the channel pore. The closing of the bilobed structure of the LBD is at least in part responsible for channel opening. Single channel recording experiments (12) have demonstrated that full and partial agonists can activate AMPA receptor channels to the same three or four distinct conductance levels. At saturating agonist concentrations in the absence of desensitization, partial agonists exhibit lower currents than full agonists because the lower conductance levels are preferentially populated relative to that seen with full agonists (12, 14, 42) . The different conductance levels have been assumed to arise from the activation of individual gates on each of four subunits (43) . That is, the highest conductance level is achieved by opening the gates for all four subunits, the next highest conductance has three open gates, and so on. At saturating concentrations of agonist, all four subunits are occupied, so in the absence of desensitization, the population of lower conductance states by partial agonists would suggest that the channel gate is not automatically triggered by the binding of agonist but rather the opening of the channel gate for an individual subunit is associated with a conformational equilibrium whose energy levels are changed upon binding agonist. Jin et al. (12) provided an elegant explanation of partial agonism based on a series of crystal structures that correlated lobe orientation in the GluA2 LBD with efficacy. The greater the closure of the lobes observed in a series of crystal structures, the greater the efficacy. The conductance states for both full and partial agonists were shown to be identical and the population of the conductance levels followed a bionomial distribution. The probability of success for the bionomial can be taken as a measure of efficacy ("efficacy factor"). The "efficacy factor" is in turn correlated with the relative lobe orientation of the LBD. This hypothesis has been termed a "static" explanation in that a relatively fixed degree of lobe closure sets the probability of the activation of a gate (44) . An alternative model ("dynamic"), but not mutually exclusive, is that each subunit exhibits a conformational ensemble that is modified by the binding of full and partial agonists. For full agonists, the conformational ensemble would favor mainly the closed lobe state and activation of the gate for the subunit; whereas, partial agonists would include a fully closed state as well as distribution of more open states, with a less frequent activation of the gate for that subunit. In the simplest version of the model, the fully closed state of the LBD would be the trigger for the activation of the channel gate and the probability of attaining a fully closed LBD would determine the efficacy.
Landes et al. (22) have shown, using single molecule FRET, that a distribution of lobe orientations can be observed in the GluA2 LBD construct, and that, compared to the wildtype protein bound to glutamate, both the apo form and the T686S mutant bound to glutamate have wider distributions, with the more open states populated to a greater extent. Also, for partial agonists such as IW, a wide range of lobe orientations has been observed using crystallography (12, 20) and NMR spectroscopy (15) . In addition, dynamics near the lobe interface suggest that large-scale lobe motions may be present when the LBD is bound to IW (21, 23) . In contrast, when the wildtype LBD is bound to kainate, the lobes are in a relatively open orientation in all crystal structures to date (4, 18, 24, 25) and this is supported by the average structure determined using NMR spectroscopy (15) . The idea has been that the lobes remain separated by a steric clash between the isoprenyl group of kainate and the sidechain of L650 (3, 18) . In addition, no evidence for lobe motions on the µs-ms timescale has been observed in the GluA2 LBD when bound to kainate (23) . Thus, the binding of kainate to the GluA2 LBD has been a strong argument against the "dynamic" hypothesis. We show here, however, that the LBD can be trapped in an almost fully closed form when bound to kainate, and the binding pocket accommodates by a small shift in the position of kainate and a change in the rotameric state of L650 ( Figure 2C ). This would suggest that, when bound to kainate, the LBD does transition to a fully closed state, albeit rarely, consistent with the low efficacy of kainate at GluA2 receptors. The caveat in all of these experiments is that the crosslinking is done using the isolated LBD, which is not constrained by the remainder the protein. Taken together with single molecule FRET experiments (22) , which clearly show a large distribution of lobe orientations in some cases, these results strongly suggest that one conformation among the ensemble is the closed lobe form. Although this does not prove that it is the closed lobe form that results in channel activation, it does show that the LBD bound to even very weak partial agonists can attain this conformation, and is consistent with the notion that the stability of the fully closed lobe may contribute to efficacy.
If the hypothesis described above is true, then antagonists should not be trapped in the fully closed state. The definition of an antagonist is somewhat arbitrary in the sense that CNQX and DNQX, which are classical antagonists of AMPA receptors, can activate the channel under some conditions (36) (37) (38) . This would suggest that, in the isolated LBD, it should be possible to detect the formation of the disulfide in the A452C/S652C mutant in the presence of CNQX and DNQX. This is clearly the case for CNQX, where a crystal structure of the closed, disulfide-bonded form was obtained. For DNQX, no disulfide-bonded crystal structure was observed, but the 1 H, 15 N-HSQC spectrum of the protein differed in the presence and absence of reducing agent, suggesting that the disulfide could be formed. On the other hand, the binding of UBP282 results in hyperextension of the lobes due to rather bulky groups that interact specifically with sites on both lobes (39) . Although this compound has a relatively low affinity, it is clearly an antagonist (40) . The 1 H, 15 N-HSQC spectra were unchanged in the presence and absence of reducing agents, suggesting that the A452C/S652C disulfide did not form. These results further support the notion that only when bound to agonists can the protein assume a fully closed state, and, in fact, even very weak partial agonists, such as CNQX and DNQX, are capable of assuming a fully closed state.
Although NMDA receptors are expressed well on the cell surface and are functional when double cysteine mutations are introduced in either NR1 or NR2 to lock the lobes closed (45, 46) , the A452C/S652C mutation of GluA2 is robustly expressed but does not reach the cell surface.
However, when expressed in bacteria, the GluA2 LBD with these mutations folds correctly and the agonist binding site is intact. Assuming the protein is properly folded but does not traffic to the cell surface, the defect in trafficking might be due either to impairment of the formation of dimers or tetramers or to the conformational state (e.g., desensitized). The L483Y mutation seems to promote tetramerization and stabilizes the interface between LBD dimers. Although the tetramers are formed, the lack of desensitization of the L483Y mutants limits trafficking to the cell surface (47, 48) . Formation of the A452C/S652C disulfide would destabilize the interface between LBD dimers and perhaps have the opposite effect on tetramerization (or even dimerization). Although desensitization may promote trafficking to the cell surface, if a tetrameric receptor were not formed, then the protein would not exit the ER.
The use of disulfide trapping has demonstrated that an essentially fully closed form of the LBD of GluA2 can be obtained in the presence of a range of partial agonists. This suggests that the lobes can show transitions to multiple conformations, as suggested previously by NMR dynamics measurements (21, 23) and single molecule FRET experiments (22) . Although these experiments do not address directly the conformation required to activate the channel, previous studies showing that partial agonists can assume a range of conformations would suggest that it is this ensemble that may determine efficacy. The finding that the fully closed form is part of that ensemble is consistent with the idea that it is the stability of the fully closed form that determines efficacy. Fig. 1 . Comparison of the amide backbone chemical shifts in the oxidized and reduced (DTT) form of A452C/S652C mutant of GluA2 LBD bound to (A) glutamate (PDB), (B) iodowillardiine (PDB), and (C) kainate (PDB). On the right is shown the 1 H, 15 N-HSQC spectrum, and on the left a representation of the resonances that have shifted upon reduction of the A452C/S652C disulfide bond. The oxidized form is identical with no additions and in the presence of CuPhen, suggesting that the disulfide bond forms spontaneously. The difference in chemical shift between the oxidized and reduced from was quantitated using:
FIGURE LEGENDS
Residues were assigned colors with the chemical_shift_difference between 0 and 5 assigned to a rainbow of colors from blue to red. (C) Kainate: The glutamate-bound structure is shown in dark blue and the wildtype kainate-bound structure is shown in tan (1FW0; 3). As seen for iodowillardiine, the A452C/S652C mutant structure (shown in green) is more closed and the D651-H 2 O-Y450 and C652-G451 H-bonds are clearly present as is the C452-C652 disulfide bond (PDB). Note the change in the rotameric state of the sidechain of L650. , or A452C/S652C GluA2 was transfected into HEK293 cells and the response to glutamate was measured using a ratiometric fura-2 imaging. Clear channel activation was observed for wildtype and S652C, but not for the double mutant. (B) Immunofluorescent labeling of HEK293 cells transfected with full-length wildtype, S652C, or A452C/S652C GluA2. In both cases, the cells were fixed in 2% paraformaldehyde prior to labeling, but the total staining was done in the presence of 0.1% Triton X-100 to allow access of the antibody to the cytoplasm. Surface staining was done in the absence of Triton X-100. The primary antibody recognized an extracellular determinant on GluA2.
